Iovance Biotherapeutics (NASDAQ:IOVA) LN-145 received FDA breakthrough therapy designation in recurrent, metastatic, or persistent cervical cancer with disease progression on or after chemotherapy.
Designed to strengthen the immune system’s anti-tumor response, LN-145 consists of a patient’s own tumor infiltrating lymphocytes that have been stimulated with IL-2 and replicated in tissue culture, which are then re-administered.
“Cervical cancer patients who have progressed on or after chemotherapy have limited treatment options. We hope to bring LN-145 to these patients as quickly as possible,” Maria Fardis, Iovance’s president and CEO, said in a statement.
Iovance is currently conducting Phase 2 trials of LN-145 in cervical; head and neck; and non-small cell lung cancers, as well as melanoma.
